1 |
NCT02379520 |
Recruiting |
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA |
- Human Papillomavirus-Related Carcinoma
- Human Papillomavirus Positive Oropharyngeal Carcinoma
- Human Papillomavirus Positive Cervical Carcinoma
- (and 3 more...)
|
- Genetic: HPV Specific T Cells
- Drug: Cytoxan
- Drug: Fludarabine
- Biological: Nivolumab
|
Interventional |
Phase 1 |
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital System
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with dose limiting toxicity (DLT)
- Overall response rate
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT02379520 |
H-36021 HESTIA |
HESTIA |
September 2015 |
October 2018 |
October 2033 |
March 5, 2015 |
April 25, 2018 |
|
- Houston Methodist Hospital
Houston, Texas, United States
|
2 |
NCT01349881 |
Recruiting |
S0820, Adenoma and Second Primary Prevention Trial |
|
- Drug: Eflornithine placebo & sulindac placebo
- Drug: eflornithine & sulindac placebo
- Drug: Eflornithine placebo & sulindac
- Drug: Eflornithine plus sulindac
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Cancer Prevention Pharmaceuticals, Inc.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- 3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)
- Incidence of colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, polyps >/= 0.3 cm, total advanced colorectal events or total colorectal events at 3 years.
- Toxicity by CTCAEv.4.0 at 3 years
- (and 3 more...)
|
1340 |
All |
18 Years and older (Adult, Senior) |
NCT01349881 |
S0820 U10CA037429 NCI-2012-02067 |
PACES |
March 2013 |
June 2024 |
June 2029 |
May 9, 2011 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 922 more...)
|
3 |
NCT01515787 |
Recruiting |
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery |
|
- Drug: FOLFOX (chemotherapy)
- Other: 5 FUCMT (chemoradiation)
- Procedure: surgery
- Procedure: magnetic resonance imaging or endorectal ultrasound
|
Interventional |
Phase 2 Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pelvic R0 resection rate (Phase II)
- DFS (Phase III)
- Time to local recurrence (TLR)
- (and 4 more...)
|
1120 |
All |
18 Years and older (Adult, Senior) |
NCT01515787 |
N1048 CDR0000715321 NCI-2012-00234 U10CA031946 |
|
January 2012 |
January 2021 |
|
January 24, 2012 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1030 more...)
|
4 |
NCT03365882 |
Recruiting |
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery |
- Colon Adenocarcinoma
- ERBB2 Gene Amplification
- Rectal Adenocarcinoma
- (and 16 more...)
|
- Biological: Cetuximab
- Drug: Irinotecan Hydrochloride
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Incidence of adverse events
- Overall response rate (ORR)
- Overall survival (OS)
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT03365882 |
S1613 NCI-2016-01422 U10CA180888 |
|
October 9, 2017 |
April 1, 2021 |
June 15, 2023 |
December 7, 2017 |
April 10, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 542 more...)
|
5 |
NCT02997228 |
Recruiting |
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer |
- Colorectal Adenocarcinoma
- Mismatch Repair Deficiency
- Stage IV Colorectal Cancer AJCC v7
- (and 2 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Drug: Fluorouracil
- (and 4 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival (OS)
- Objective response rate (ORR) (complete response [CR] or partial response [PR]) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- (and 5 more...)
|
347 |
All |
18 Years and older (Adult, Senior) |
NCT02997228 |
NCI-2016-01961 NRG-GI004/S1610 NRG-GI004 U10CA180868 |
|
November 7, 2017 |
April 30, 2022 |
April 30, 2022 |
December 20, 2016 |
April 24, 2018 |
|
- John Muir Medical Center-Concord Campus
Concord, California, United States - Fremont - Rideout Cancer Center
Marysville, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 150 more...)
|
6 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054 EAY131 U10CA180820 U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 24, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1212 more...)
|
7 |
NCT02921256 |
Recruiting |
Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer |
- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7
|
- Drug: Capecitabine
- Drug: Fluorouracil
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in NAR score
- OS
- DFS
- (and 11 more...)
|
174 |
All |
18 Years and older (Adult, Senior) |
NCT02921256 |
NCI-2016-00222 NRG-GI002 s17-00197 U10CA180868 |
|
October 12, 2016 |
April 30, 2019 |
|
October 3, 2016 |
April 23, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 515 more...)
|
8 |
NCT02685631 |
Recruiting |
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study |
- Localized Non-Resectable Adult Liver Carcinoma
|
- Other: Yttrium-90 Resin Microspheres
|
Observational |
|
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease
- Treatment related toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4) measures
- Overall Survival
- Time to Progression
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT02685631 |
VICCGI1523 NCI-2015-01837 VICC GI 1523 P30CA068485 |
RESiN |
July 2015 |
August 2020 |
August 2021 |
February 19, 2016 |
February 8, 2017 |
|
- University of Alabama
Birmingham, Alabama, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - California Pacific Medical Center
San Francisco, California, United States - (and 23 more...)
|
9 |
NCT02711137 |
Recruiting |
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies |
|
- Drug: INCB057643
- Drug: Gemcitabine
- Drug: Paclitaxel
- (and 4 more...)
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of INCB057643 as monotherapy and in combination with standard of care (SOC) agents in patients with advanced malignancies; assessed by clinical laboratory assessments, physical examinations, 12 lead ECGs, and adverse events (AEs)
- Pharmacokinetics of INCB057643 as monotherapy in the fasted state and in the fed state (food effect; Part 2 only) and when administered in combination with Standard of Care (SOC) agents in the fasted state assessed by plasma and urine concentrations
- Measurement of cellular myc protein concentrations before and after administration of INCB057643 when administered as monotherapy
- (and 7 more...)
|
420 |
All |
18 Years and older (Adult, Senior) |
NCT02711137 |
INCB 57643-101 |
|
May 2016 |
November 2021 |
December 2021 |
March 17, 2016 |
March 27, 2018 |
|
- University of Alabama
Birmingham, Alabama, United States - University of California
La Jolla, California, United States - Sarah Cannon Research Institute at Health One
Denver, Colorado, United States - (and 16 more...)
|